for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regenxbio Inc

RGNX.O

Latest Trade

35.85USD

Change

-0.10(-0.28%)

Volume

9,088

Today's Range

35.20

 - 

36.14

52 Week Range

26.40

 - 

50.26

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
35.95
Open
35.71
Volume
9,088
3M AVG Volume
10.47
Today's High
36.14
Today's Low
35.20
52 Week High
50.26
52 Week Low
26.40
Shares Out (MIL)
42.60
Market Cap (MIL)
1,531.49
Forward P/E
-10.09
Dividend (Yield %)
--

Next Event

Q3 2021 Regenxbio Inc Earnings Release

Latest Developments

More

Abbvie And Regenxbio Announce Eye Care Collaboration

Regenxbio Reports Second Quarter 2021 Financial Results And Operational Highlights

Abeona Intends To Seek Enforcement Of Settlement Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Regenxbio Inc

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates use adeno-associated virus (AAV) vectors from its gene delivery platform, called NAV Technology Platform. Its product candidate includes RGX-314, RGX-111, RGX-121, RGX-202, RGX 181 and RGX-381. RGX-314 is meant for the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) and other anti-VEGF treated conditions. It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II). RGX-202 is its product candidate for the treatment of duchenne muscular dystrophy (DMD).

Industry

Biotechnology & Drugs

Contact Info

9804 MEDICAL CENTER DRIVE

ROCKVILLE, MD

20850

United States

+1.240.5528181

http://regenxbio.com/

Executive Leadership

Allan M. Fox

Chairman of the Board

Kenneth T. Mills

President, Chief Executive Officer, Director

Vittal K. Vasista

Chief Financial Officer, Senior Vice President

Curran M. Simpson

Senior Vice President, Chief Operations and Technology Officer

Olivier Danos

Senior Vice President, Chief Scientific Officer

Key Stats

2.00 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.2K

2019

0.0K

2020

0.2K

2021(E)

0.1K
EPS (USD)

2018

2.730

2019

-2.580

2020

-2.980

2021(E)

-3.561
Price To Earnings (TTM)
--
Price To Sales (TTM)
9.50
Price To Book (MRQ)
3.02
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-25.16
Return on Equity (TTM)
-22.58

Latest News

Latest News

UPDATE 3-Regenxbio to receive $370 mln upfront in gene therapy deal with AbbVie

AbbVie will pay $370 million upfront to Regenxbio Inc in a deal to develop and sell an experimental gene therapy for the treatment of chronic retinal diseases, the companies said on Monday.

AbbVie, Regenxbio enter deal to develop retinal disease therapy

AbbVie and Regenxbio Inc have entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, the pharmaceutical companies said on Monday.

BRIEF-Regenxbio Says RGX-111 And RGX-121 Continue To Be Well-Tolerated In Patients

* REGENXBIO PROVIDES UPDATE ON PROGRESS OF CLINICAL PROGRAMS FOR RARE GENETIC NEURODEGENERATIVE DISEASES

BRIEF-Regenxbio Announces Additional Positive Long-Term And Interim Phase I/Iia Trial Update For Rgx-314 For The Treatment Of Wet AMD

* REGENXBIO ANNOUNCES ADDITIONAL POSITIVE LONG-TERM AND INTERIM PHASE I/IIA TRIAL UPDATE FOR RGX-314 FOR THE TREATMENT OF WET AMD

BRIEF-Regenxbio And Ultragenyx Announce New License Agreement For Use Of Nav Technology Platform For Treatment Of Rare Metabolic Disorder

* REGENXBIO AND ULTRAGENYX ANNOUNCE NEW LICENSE AGREEMENT FOR USE OF NAV® TECHNOLOGY PLATFORM FOR THE TREATMENT OF RARE METABOLIC DISORDER

BRIEF-Regenxbio Posts Q4 Loss Per Share Of 72 Cents

* REGENXBIO REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

BRIEF-Regenxbio Announces First FDA Approval Of A Gene Therapy Based On Its Proprietary Nav Technology Platform

* REGENXBIO ANNOUNCES FIRST FDA APPROVAL OF A GENE THERAPY BASED ON ITS PROPRIETARY NAV® TECHNOLOGY PLATFORM

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up